Literature DB >> 11462748

Psychostimulants in the treatment of adults with psychosis and attention deficit disorder.

L A Opler1, D M Frank, P M Ramirez.   

Abstract

Whether conceptualized as comorbid ADD with psychosis or as a distinct diagnostic entity--ADD psychosis--patients with features of both ADD and psychosis benefit from treatment with psychostimulants. It is hypothesized that psychostimulants have their therapeutic effect via amelioration of frontal lobe dysfunction.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11462748     DOI: 10.1111/j.1749-6632.2001.tb05786.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  6 in total

1.  The 10th Anniversary of the Eli Lilly Chair of Schizophrenia from the University of Montreal.

Authors:  Emmanuel Stip; Stéphane Potvin
Journal:  Can J Psychiatry       Date:  2015-03       Impact factor: 4.356

Review 2.  Raising attention to attention deficit hyperactivity disorder in schizophrenia.

Authors:  Stefano Pallanti; Luana Salerno
Journal:  World J Psychiatry       Date:  2015-03-22

Review 3.  Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder.

Authors:  C Mehler-Wex; P Riederer; M Gerlach
Journal:  Neurotox Res       Date:  2006-12       Impact factor: 3.911

Review 4.  Psychotic disorders comorbid with attention-deficit hyperactivity disorder: an important knowledge gap.

Authors:  Emmanuelle Levy; Alexandru Traicu; Srividya Iyer; Ashok Malla; Ridha Joober
Journal:  Can J Psychiatry       Date:  2015-03       Impact factor: 4.356

5.  The Epigenetic Mechanisms of Amphetamine.

Authors:  Talus J McCowan; Archana Dhasarathy; Lucia Carvelli
Journal:  J Addict Prev       Date:  2015-02-09

Review 6.  Vitamin D receptor and epigenetics in HIV infection and drug abuse.

Authors:  Nirupama Chandel; Ashwani Malhotra; Pravin C Singhal
Journal:  Front Microbiol       Date:  2015-08-19       Impact factor: 5.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.